BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36000815)

  • 1. Post-recurrence survival analysis of patients with pulmonary recurrence from gynaecologic cancers: a multi-institutional analysis of 122 patients.
    Ersak B; Akar S; Demirayak G; Tokalioğlu AA; Aytekin O; Çakir C; Yüksel D; Tokgözoğlu N; Karakaş S; Önder AB; Çelik F; Ayhan S; Ünsal M; Boran N; Kiliç F; Cömert GK; Üreyen I; Toptaş T; Korkmaz V; Özdemir İA; Taşçi T; Türkmen O; Moraloğlu Tekin Ö; Engin-Üstün Y; Turan T
    J Obstet Gynaecol; 2022 Oct; 42(7):3277-3284. PubMed ID: 36000815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary recurrence after radical hysterectomy for uterine cervical carcinoma.
    Kilic C; Yuksel D; Cakir C; Karalok A; Boyraz G; Moraloglu Tekin O; Turan T
    J Obstet Gynaecol; 2020 Nov; 40(8):1155-1159. PubMed ID: 32027187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
    Kongsawatvorakul C; Charakorn C; Chittithaworn S; Lertkhachonsuk AA
    J Obstet Gynaecol; 2022 Aug; 42(6):2331-2335. PubMed ID: 35470751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].
    He Y; Wang Y; Ji C; Liu Y; Wu YM
    Zhonghua Fu Chan Ke Za Zhi; 2022 May; 57(5):352-360. PubMed ID: 35658326
    [No Abstract]   [Full Text] [Related]  

  • 5. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No. 385-Indications for Pelvic Examination.
    Evans D; Goldstein S; Loewy A; Altman AD
    J Obstet Gynaecol Can; 2019 Aug; 41(8):1221-1234. PubMed ID: 31331610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
    Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
    Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Referral patterns for gynaecologic cancers and precancerous conditions.
    Gagliardi A; DePetrillo D; Elit L
    J Obstet Gynaecol Can; 2002 Jul; 24(7):553-8. PubMed ID: 12196846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study.
    Wong CN; Wong CN; Liu FS
    Taiwan J Obstet Gynecol; 2017 Jun; 56(3):302-305. PubMed ID: 28600037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of major gynaecologic cancer surgery without routine preoperative COVID-19 testing in the COVID-19 era: a multicentre, retrospective, case-control study.
    Oz M; Meydanli MM; Altintas MI; Akilli H; Gultekin M; Ozgul N; Salman MC; Taskin S; Yaprak E; Taskiran C; Vatansever D; Giray B; Yetkinel S; Celik H; Onan MA; Ayhan A
    J Obstet Gynaecol; 2022 Jul; 42(5):1286-1292. PubMed ID: 34704523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
    Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
    Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
    J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
    Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
    Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Ferrero AM; Teti G; Cristofani R; Sartori E
    Gynecol Oncol; 2010 Mar; 116(3):358-63. PubMed ID: 19954826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
    Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
    Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic and survival analyses of synchronous primary endometrial and epithelial ovarian cancers.
    Sozen H; Vatansever D; Iyibozkurt AC; Topuz S; Ozsurmeli M; Salihoglu Y; Guzelbey B; Berkman S
    J Obstet Gynaecol Res; 2015 Nov; 41(11):1813-9. PubMed ID: 26369625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy.
    Clavero JM; Deschamps C; Cassivi SD; Allen MS; Nichols FC; Barrette BA; Larson DR; Pairolero PC
    Ann Thorac Surg; 2006 Jun; 81(6):2004-7. PubMed ID: 16731120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.